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Background: Esophageal squamous cell carcinoma (ESCC) shows geographic variations in incidence, with high
incidences (>50/105 person-years) in central Asia, including North Eastern Iran (Golestan) and Northern India
(Kashmir). In contrast to Western countries, smoking does not appear to be a significant risk factor for ESCC in
central Asia. In lung adenocarcinoma, activating mutations in the gene encoding epidermal growth factor receptor
(EGFR) are frequent in tumors of never smokers of Asian origin, predicting therapeutic sensitivity to Egfr-targeting
drugs.
Methods: In this study 152 cases of histologically confirmed ESCC from Iran (Tehran and Golestan Province) and
North India (Kashmir Valley) have been analyzed for EGFR mutation by direct sequencing of exons 18–21. Egfr
protein expression was evaluated by immunohistochemistry in 34 samples from Tehran and HER2 mutations were
analyzed in 54 cases from Kashmir.
Results: A total of 14 (9.2%) EGFR variations were detected, including seven variations in exons. Among those, four
(2.6%) were already documented in lung cancers, two were reported as polymorphisms and one was a potentially
new activating mutation. All but one variation in introns were previously identified as polymorphisms.
Over-expression of Egfr was detected in 22/34 (65%) of tested cases whereas no HER2 mutation was found in 54
cases from Kashmir.
Conclusion: Overall, EGFR mutations appear to be a rare event in ESCC in high incidence areas of central Asia,
although a very small proportion of cases may harbor mutations predicting sensitivity to anti-Egfr drugs.
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Esophageal cancer is the eighth most common cancer
and sixth cause of cancer death worldwide, with the
majority of cases occurring in low and middle resource
countries [1]. Esophageal Squamous Cell Carcinoma
(ESCC) represents about 80% of the cases worldwide
and is by far the most common histological type in
low-resource countries, whereas adenocarcinoma* Correspondence: pierre.hainaut@i-pri.org
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distribution, and reproduction in any mediumrepresents 20-50% of the cases in some Western coun-
tries [2]. There are striking geographic variations in in-
cidence. Very high incidence rates have been
consistently reported in a region of central Asia that
extents from the Caspian Sea to central China, defin-
ing the so called “Asian Esophageal Cancer Belt” [3,4].
North eastern Iran (Golestan) and Northern India
(Kashmir Valley) are part of this high incidence region.
Current cancer registration in Golestan shows inci-
dence rates of about 50/105 person-years in both gen-
ders [5,6]. Although there is no continuous cancer
registration in Kashmir, observational studies suggest
incidence rates of 42 and 27/105 person-years for menCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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countries, ESCC occurs at lower incidence rates (3-20/
105 person-years) with a male to female ratio of 8–10:1
[2] and frequently develops in subjects with high com-
bined tobacco and alcohol consumption. ESCC in cen-
tral Asia often develops in subjects with no smoking
and/or drinking history. Risk factors include consump-
tion of hot beverages and deprivation status. Recently,
a role for polycyclic aromatic hydrocarbons as poten-
tial mutagens in the esophageal mucosa of subjects
from Iran has been documented [8]. However, the
etiology of ESCC in central Asia is still largely un-
known [5].
Independent of geographic origin, molecular changes
in ESCC include frequent loss of alleles at chromosomes
3p, 5q, 9p and q, 13q, 17p, 17q or 18q, mutations in
tumor suppressor genes such as TP53, and genetic and/
or epigenetic alterations in CDKN2a, CCDN1, MYC1
FHIT, FEZ1, DLC1, Annexin-1, CCNB1, TP63, TP73 or
DCC [9-15]. Increased expression of Epidermal Growth
factor Receptor (Egfr), sometimes associated with ampli-
fication of EGFR gene, has been observed in a subset of
ESCC [16-18]. EGFR and its homolog HER2 belong to
the ErbB family of genes encoding transmembrane re-
ceptor tyrosine kinase receptors (RTK) which consist of
four closely related genes, EGFR (HER1/ErBb1), HER2
(ErbB2), HER3 (ErbB3) and HER4 (ErbB4). Mutations in
the RTK domain of EGFR activate the kinase activity by
a ligand-independent mechanism. Such mutations are
common in adenocarcinomas arising in never-smokers,
particularly in women and in patients of Asian origin,
and are associated with therapeutic sensitivity to drugs
inhibiting the tyrosine kinase (TKIs) [19,20]. However,
only few studies have evaluated EGFR mutations in
esophageal adenocarcinoma [20] or ESCC [17,21-25].
Overall, these reports have identified only rare muta-
tions, with the exception of a recent study focusing on
basaloid squamous cell carcinoma subtype in Japanese
patients, which reported EGFR mutations in 14% of the
cases [26].
Here we have analyzed EGFR mutations in EGFR
TK domain (exons 18 to 21) in a total number of
152 ESCC from Iran and India (Kashmir), two areas
of the “Asian Esophageal Cancer Belt” where smoking
and alcohol drinking are not significant risk factors at
population level. We hypothesized that, similar to
lung cancers of non-smokers, EGFR mutations might
be more common in this etiological context than in
ESCC occurring in the “Western” context of heavy
combined tobacco and alcohol use. HER2 mutations
(exons 19 and 20) which have also been observed in
a subset of lung cancers of never-smokers [27] and
Egfr protein expression were also analyzed in a subset
of the cases.Methods
Patients
A total of 152 surgically resected or biopsy samples of
histologically confirmed ESCC cases were retrieved from
pathology archives of hospitals in Iran and India/
Kashmir. Cases from Iran (n=98) included 64 biopsies
form patients living in Golestan and 34 surgically
resected specimens from patients treated in referral cen-
ters in Tehran. The cases from Golestan were obtained
in the course of the Golestan Case Control study
(GCCS, conducted between 2003 and 2007 as a collab-
orative study between Digestive Disease Research Insti-
tute (DDRI), USA National Cancer Institute (NCI) and
International Agency for Research on Cancer (IARC,
Lyon)) [5,28,29]. They were all analyzed for EGFR muta-
tions. The cases from Tehran were from patients treated
in three referral centers for esophagectomy (Iran Mehr,
Modarres and Madaen Hospitals) between 1991 and
1998. Resected specimens from Tehran were analyzed
for EGFR mutations and immunohistochemical detec-
tion of Egfr. The cases from Kashmir Valley included 54
ESCC from patients treated at the Departments of Car-
diovascular and Thoracic Surgery and Gastroenterology
of the Sher-I-Kashmir Institute of Medical Sciences,
Soura, Srinagar, Jammu and Kashmir, between 2002 and
2003. Resected specimens from 17 patients and 37 endo-
scopic biopsy specimens with confirmed diagnosis of
ESCC were included. This series was analyzed for EGFR
and HER2 mutations. Informed consent was obtained
for GCCS patients. No consent was available for retro-
spective, archival specimens from Tehran and Kashmir.
The study, including anonymized use of archival speci-
mens, was approved by ethical review boards of the
DDRI in Iran and the Kashmir Institute of Medical
Sciences, Soura, Srinagar Kashmir.
Mutation analysis
Tumor samples were fixed in 10% buffered formalin, ex-
cept for a subset of cases from the GCCS which were
fixed in 70% ethanol, and all paraffin-embedded. In a
previous study, we have shown that there was no bias in
DNA extraction and mutation detection between these
two fixation methods [30]. Areas with at least 50%
tumor cells were selected on 4 μm unstained sections
and were scraped off with a disposable scalpel blade.
DNA extraction was performed using the QIAamp DNA
microkit (QIAGEN, Hilden, Germany). EGFR mutation
analysis was performed by PCR-based direct sequencing
of exons 18 to 21 (tyrosine kinase domain) using primers
and annealing conditions as described by Pao et al. [31]
and Go-Taq polymerase (Promega, Madison, WI, USA).
HER2 was amplified for exons 19 and 20 using the pri-
mers and annealing conditions described by Mounawar
et al. [27]. PCR products were sequenced using Applied
Table 2 Patients’ characteristics
Characteristics Iran India Total
No (%) No (%) No (%)
Total No of cases 98 54 152
Age Mean 63.0 57.0
Range 27-84 35-75
Gendera Male 44 (45.8) 36 (66.7) 80 (46.7)
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method (Perkin-Elmer, Foster City, CA) on ABI PRISM
3100 Genetic Analyzer (Applied Biosystems, Foster City,
CA). All PCR products were sequenced in both forward
and reverse directions. Presence of mutations was con-
firmed by a second independent PCR amplification and
sequencing.a Data available for analysis for 150 cases.Immunohistochemistry
Sections (4 microns) were prepared from paraffin blocks
of 34 cases from Tehran, all formalin-fixed. After depar-
affinization, inactivation of endogenous peroxidases was
done by incubating sections for 40 minutes in 0.3%
H2O2 in methanol. Antigen unmasking was performed
in citrate buffer pH 6 for 10 minutes in a high pressure
high temperature cooker. Slides were then incubated
with mouse monoclonal antibody to Egfr (Novocastra, 1/
10 dilution) for 1 hour, followed by secondary anti-
mouse antibody coupled to peroxidase (Immpress re-
agent anti-mouse Ig peroxidase, Vector Laboratories, 1/
200), diaminobenzidine (DAB)-based revelation and
counterstaining with hematoxylin. For each section a
negative control was stained without primary antibody.
Staining intensity was scored using a four-tier system as
defined in Table 1. Samples scored as 2+ or 3+ were
considered as “over-expression” [17].Results
A total of 152 cases of primary invasive ESCC samples were
analyzed, including 54 specimens from Indian (Kashmiri)
patients and 98 specimens from Iranian patients (Table 2).
EGFR mutations were analyzed by sequencing exons 18 to
21 in all samples. A total of 14 (9.2%) different variations
were detected, eight (5.3%) have been reported as known
polymorphisms, including a common polymorphism at
codon 787 (rs1050171, c.2361 G>A), occurring with a glo-
bal allelic frequency of 0.417. (http://www.1000genomes.
org/ensembl-browser) (Table 3). Four variations (2.6%)
were identical to potential or demonstrated activating
mutations in EGFR TK domain already reported in other
cancers, in particular NSCLC (http://www.sanger.ac.uk/
genetics/CGP/cosmic/) (Table 4) and two variations (1.3%)
have never been reported in any available database (a one-
bp deletion in exon 20 (c.2373) and an intronic one (c.2625Table 1 Definition of Immunostaining scores for egfr protein
numbers=34)
Score Definition
0 No staining or backgroun
1+ Definite cytoplasmic staining and/or equivocal
2+ Unequivocal membrane staining with modera
3+ Strong, continuous membrane stainin+68)) (Table 3). These 10 variations were not considered as
potential activating EGFR mutations.
Among the four activating mutations, three were
found in ESCC cases from Kashmir, including one 15 bp
deletion in exon 19, (codons 746–750), one missense
mutation at codon 719 (exon 18, GGC to GAC, G to D)
and one missense mutation at codon 753 (exon 19; CCG
to CTG, P to L.). One missense mutation was found in
the series from Tehran, located in exon 19 at codon 730
(CTC to CCC, L to P).
Both series have been previously analyzed for TP53
mutations [30,32,33]. Of the four cases with potential ac-
tivating EGFR mutations, two also carried a mutation in
TP53 (V173G in the case from Tehran; R175H in the
case from Kashmir with the G719D EGFR mutation).
The series from Kashmir was also analyzed for muta-
tions in exons 19 and 20 of HER2, encoding a tyrosine
kinase receptor closely related to EGFR. No mutation
was found. Egfr expression status was analyzed by
immunohistochemistry in the series from Tehran. Over-
expression (staining scores 2+ or 3+) was detected in
65 % of the cases (22 of 34) whereas 26 % (9 of 34)
were scored as 0 and 9% (3 of 34) were scored as 1+,
comparable to staining intensity in normal epithelium
(Table 1). Among mutated cases, only the one with
L730P EGFR mutation showed Egfr over-expression
and was scored as 2+ (Figure 1).
Discussion
Mutations in EGFR have attracted attention because of
their common occurrence in lung cancers of non-
smokers (in particular in adenocarcinoma, women, and
patients of Asian origin) and because of their signifi-
cance as predictors of response to therapeutic tyrosine
kinase inhibitors [19,34,35]. In lung cancer, EGFRexpression in ESCC cases from Tehran (total examined
Number (%)
d-type staining 3 (8.8)
discontinuous membranous staining 9 (26.5)
te intensity in over 10%of the cells 16 (47.0)
g in over 10% of the cells 6 (17.7)
Table 3 EGFR variations detected in Golestan ESCC cases with unknown impact on TK domain (according to
"1000genomes" database)a
Exon/Intron Genomic number Description Frequency of detection SNP ID
18-Intron 155112 c.2184+100C>T 3 rs17290336
18-Intron 155031 c.2184+19G>A 6 rs17337107
18-Intron 155593 c.2185-98C>T 1b rs62507090
19-Intron 155858 c.2283+69G>A 1c rs17337135
19-Intron 162202 c.2284-60T>C 21 rs10241451
19-Intron 162241 c.2284-21C>T 4 ESP_7_55248965d
20-Exon 162339 c.2361A>G 51 rs1050171
20-Exon 162435 c.2457G>A 1 rs56183713
20-Exon 162351 c.2373del1 11 Not reported
21-Intron 172911 c.2625+68C>T 1 Not reported
a http://www.1000genomes.org/ensembl-browser.
b This case has also TP53 mutation at exon 6, codon 211 (G:C>A:T).
c This case has also TP53 mutation at exon 6, codon 217 (deletion1).
d Reported from NHLBI GO Exome sequencing project.
Abedi-Ardekani et al. BMC Cancer 2012, 12:602 Page 4 of 7
http://www.biomedcentral.com/1471-2407/12/602mutations cluster in exons 18 to 21, encoding the do-
main of the tyrosine kinase that contains the ATP bind-
ing pocket. The most common mutations are short, in
frame deletions in exon 19 (34%) and missense muta-
tions at codon 858 (p.L858R) in exon 21 (36%) (http://
www.sanger.ac.uk/genetics/CGP/cosmic/). These muta-
tions modify the geometry of the ATP binding cleft in
the tyrosine kinase, resulting in a hyperactive form of
the receptor. These are not restricted to lung adenocar-
cinoma and we have reported two mutations among four
lifetime never-smokers with squamous cell carcinoma of
the lung [27]. Mutations are infrequent in other cancer
pathologies analyzed to date [20,36].
Based on the hypothesis that these mutations may pre-
ferentially occur in a context of non-tobacco dependent
carcinogenesis, we investigated whether EGFR mutations
could be detected in three series of ESCC from central
Asia (two high incidence areas in Northern Iran (Gole-
stan) and Northern India (Kashmir) and one low inci-
dence area in Iran (Tehran). The etiology of ESCC in
these areas has been addressed in a number of studies
[5,7,8,28,37,38]. Overall, epidemiological studies have
consistently reported that tobacco usage is not a signifi-
cant risk factor, in contrast with ESCC detected in most
Western countries and in Japan. Sequencing of exons 18
to 21 of EGFR in a total of 152 ESCC cases detected 14
variations (9.2%). Comparison with COSMIC database
indicates that four of these variations are knownTable 4 Known activating EGFR mutations found in 152 patie
Origin of the patient Tehran
Mutation type Missense M
Exon No. 19
Nucleotide change c.2188C>T c.2
Amino acid change p.L730F p
a http://www.sanger.ac.uk/genetics/CGP/cosmic/.activating mutations in EGFR TK domain (2.6%), includ-
ing a common deletion (p.Q746_A750del; 560 occur-
rences in the COSMIC database) and three less
common missense mutations. The other variations iden-
tified in this study are known polymorphisms except for
two unknown never reported variations which is not
clear whether they may activate the tyrosine kinase in
the same way as well-characterized EGFR activating
mutations.
Previous studies have shown that EGFR activating
mutations were rare in ESCC. In a study of 57 cases,
Guo et al. reported three EGFR mutations, including a
truncating mutation at E872 and two silent mutations at
G873 and P753 [23]. In another series of 40 cases (15 of
which with amplification of Egfr), Hanawa et al. did not
detect any mutation in exon 19 or 21 [17]. To our know-
ledge, the only study in which a significant proportion of
cases contained EGFR mutation (14%) was focused on a
rare variant form, basaloid squamous cell carcinoma,
suggesting that aberrations in EGFR may be involved in
this particularly aggressive form of the disease [26]. Not-
ably, the series analyzed here does not include basaloid
forms of ESCC but comprises cases from Golestan, an
area in which we have previously reported an extremely
high rate of TP53 mutations (90%), suggestive of the role
of diverse mutagens in esophageal carcinogenesis [30].
Thus, contrary to our hypothesis, and regardless of in-
volvement of environmental mutagens in ESCC fromnts (according to COSMIC database)a
India India India
issense Missense Microdeletion
18 19 19
156G>A c.2203C>T c.2235del15
.G719D p.P753L p.Q746_A750
Figure 1 EGFR expression in normal esophageal epithelium and ESCC. a-Normal esophageal epithelium with background and weak
cytoplasmic staining, scored as 1+; b- ESCC patient from Tehran with EGFR mutation (L730F) and protein expression of 2+ positivity; c- ESCC with
strong (3+) positive staining in compared with negative normal epithelium; d- negative control. (Magnification ×200).
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patients appears to be a rare event which may not play a
significant role in the pathogenesis of ESCC. Further
studies are needed to determine such EGFR mutations
tend to occur at higher frequency in specific groups of
ESCC patients.
Despite infrequent mutations in EGFR, over expres-
sion of the protein, with or without gene amplification,
is a relatively frequent event in ESCC [16-18,39-41]. In
2006, Hanawa et al. reported that, among 53 cases of
ESCC with high protein expression levels, FISH analysis
of amplification revealed clear amplification in 15 cases,
evidence for modest changes in copy numbers in 32
cases and no evidence for amplification in six cases,
clearly showing that amplification is only partially corre-
lated with expression [17]. In the present series, we
detected Egfr over expression in 65% of the cases, irre-
spective of tumor grade and stage. However, we have
not analyzed the amplification status of the EGFR locus.
The only case with known EGFR activating mutation
expressed Egfr at moderate levels. The frequent over-
expression of Egfr has led to the concept that Egfr-
targeting therapies may have some benefit in patients
with advanced esophageal cancer. A phase II study of
Gefinitib, an Egfr tyrosine kinase inhibitor, in second-
line treatment of advanced esophageal cancer, reported
that a significantly higher disease control rate (res-
ponse plus stable disease) was observed in patients
with ESCC histology or with high Egfr expression [42].
These results concur with ours to suggest that furtherefforts should be made to select esophageal cancer
patients who may benefit from Egfr-targeted therapies.
Conclusions
This report is the first report for identification of EGFR
activating mutations in ESCC. Previous studies failed to
identify such mutations. Focusing our analysis on groups
of non-smoking patients from Asia, we found rare acti-
vating mutations (4/152 cases, 2.6%) but frequent Egfr
protein over-expression (65%). These results suggest that
further efforts should be developed to determine
whether EGFR mutations occur in specific groups of
ESCC patients and whether these esophageal cancer
patients may benefit from Egfr-targeted therapies.
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